Eribulin for heavily pre-treated metastatic breast cancer patients

Antonia Digklia; Ioannis A Voutsadakis

文献导航

搜索文章

搜索思路

钛学术文献服务平台 \
学术期刊 \
综合期刊 \
其它期刊 \
世界实验医学杂志期刊 \
Eribulin for heavily pre-treated metastatic breast cancer patients

Eribulin for heavily pre-treated metastatic breast cancer patients

作者：

Antonia Digklia Ioannis A Voutsadakis

基本信息来源于合作网站，原文需代理用户跳转至来源网站获取

BREAST

cancer

METASTATIC

ERIBULIN

Case

series

RETROSPECTIVE

Treatment

摘要：

AIM:To discuss treatment with eribulin in clinical practice outside a clinical trial.METHODS:Archives of patients treated for metastatic breast cancer were reviewed and 21 patients treated with the new chemotherapeutic eribulin mesylate,a synthetic analog of a natural marine product,were identified.Information on patients’characteristics and treatment outcomes was extracted.Treatment with eribulin mesylate was initiated at the recommended dose of 1.4 mg/m2 on days 1 and 8 of a 21-day cycle in 17 patients and at a decreased dose of 1.1 mg/m2 on days 1 and 8 of a 21-day cycle in 4 patients due to comorbidities and frailty.Efficacy of the drug was evaluated using the revised Response Evaluation Criteria in Solid Tumors criteria.Progression-Free Survival and overall survival(OS)were calculated using the Kaplan-Meier method starting from the date of eribulin therapy initiation to the date of disease progression documentation or death,respectively.RESULTS:The median age of patients at the time of eribulin mesylate treatment was 53 years(range 34-75).Sixteen patients had estrogen receptor(ER)and/or partial response(PR)positive disease and 5 had ER/PR negative disease(all triple negative).Eight patients had received 2 or 3 previous lines of chemotherapy for metastatic disease and 13 patients had received 4 or more lines of treatment.The median number of cycles of eribulin received was 3(range 1-16 years).All patients,except one,discontinued treatment due to progressive disease and one patient due to adverse effects.Six patients had a dose reduction due to side effects.All patients had progressed at the time of the report with a median time to progression of 3 mo(range 1 to 14 mo).Fifteen patients had died with a median OS of 7 mo(range 1-18 mo).Six patients were alive with a median follow-up of 13.5 mo(range 7 to 19 mo).CONCLUSION:This series of patients confirms the activity of eribulin in a heavily pre-treated metastatic breast cancer population consistent with phaseⅡandⅢtrials.

内容分析

关键词云

关键词热度

相关文献

推荐文献

根据相关规定，获取原文需跳转至原文服务方进行注册认证身份信息

完成下面三个步骤操作后即可获取文献，阅读后请点击下方页面【继续获取】按钮

钛学术文献服务平台

学术出版新技术应用与公共服务实验室出品

原文合作方

获取文献流程

1.访问原文合作方请等待几秒系统会自动跳转至登录页，首次访问请先注册账号，填写基本信息后，点击【注册】

2.注册后进行实名认证，实名认证成功后点击【返回】

3.检查邮箱地址是否正确，若错误或未填写请填写正确邮箱地址，点击【确认支付】完成获取，文献将在1小时内发送至您的邮箱

*若已注册过原文合作方账号的用户，可跳过上述操作，直接登录后获取原文即可

点击【获取原文】按钮，跳转至合作网站。

首次获取需要在合作网站进行注册。

注册并实名认证，认证后点击【返回】按钮。

确认邮箱信息，点击【确认支付】，订单将在一小时内发送至您的邮箱。

* 若已经注册过合作网站账号，请忽略第二、三步，直接登录即可。

期刊分类
期刊（年）
期刊（期）
期刊推荐

其它

世界实验医学杂志2021 世界实验医学杂志2020 世界实验医学杂志2019 世界实验医学杂志2018 世界实验医学杂志2017 世界实验医学杂志2016 世界实验医学杂志2015 世界实验医学杂志2014 世界实验医学杂志2013 世界实验医学杂志2012 世界实验医学杂志2011

世界实验医学杂志2015年第4期世界实验医学杂志2015年第3期世界实验医学杂志2015年第2期世界实验医学杂志2015年第1期

按字母查找期刊：

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
其他

联系合作广告推广: shenyukuan@paperpass.com

篇名	Eribulin for heavily pre-treated metastatic breast cancer patients
来源期刊	世界实验医学杂志	学科	医学
关键词	BREAST cancer METASTATIC ERIBULIN Case series RETROSPECTIVE Treatment
年，卷（期）	2015,（3）	所属期刊栏目
研究方向		页码范围	194-199
页数	6页	分类号	R
字数		语种
DOI